Special Issue "Pancreatic Cancer: Challenges and Breakthroughs"
Deadline for manuscript submissions: 15 May 2021.
Interests: pancreatic cancer; cholangiocarcinoma; early diagnosis; photodynamic therapy; nanomedicine; organoids
Pancreatic cancer is an extremely lethal disease. It is difficult to detect early due to patients presenting vague symptoms, and thus is difficult to treat effectively leading to high rates of recurrence. Although advances in imaging techniques have been made, current imaging methods and biomarker panels to detect the disease in patients at high-risk of developing cancer, lack the necessary sensitivity and specificity for routine use in early detection screenings. Over the last years, many preclinical studies and clinical trials have been conducted trying to improve patient outcomes. Altogether, those studies led to deepening our understanding of disease development and progression, and to deciphering molecular pathways and mechanisms of resistance to therapy. Nonetheless, some key challenges remain to be addressed. Because of those, current efforts seek to advance research progress toward: a) improving treatment options and establishing new therapeutic strategies to overcome drug resistance; b) discovering new drug targets; c) performing molecular profiling; and d) advancing early detection.
The present Special Issue aims to address “Pancreatic Cancer: Challenges and Breakthroughs” by assembling significant contributions in the following categories:
- Present challenges: future directions for improving outcomes
- Novel therapeutic strategies, such as but not limited to: personalized medicine, combination and targeted therapy, immunotherapy, new therapeutic targets, tumor metabolism
- Insights into early detection: biomarkers, new imaging techniques, AI
- Tumor microenvironment: tumor microbiome, disease modeling, tumor-stroma interactions, inflammation
- Drug resistance and disease recurrence: prognostic markers, cancer stem cells, circulating tumor cells, tumor heterogeneity
I hope this scope will encourage the participation of researchers and clinicians, who would like to address future directions to improve the outcome of pancreatic cancer patients. Contributions can be made in the format of research articles, reviews, communications, perspectives, opinions, concept papers, and case studies.
Dr. Maria Del Pilar Acedo Nunez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Novel therapeutics
- Early detection
- Tumor microenvironment
- Disease recurrence